Generali Investments CEE’s Novartis NVS Stock Holding History

Generali Investments CEE’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.88M	Hold	12,000	–	–	0.09%	220
2026 Q1	$1.83M	Hold	12,000	–	–	0.1%	223
2025 Q4	$1.65M	Hold	12,000	–	–	0.12%	196
2025 Q3	$1.54M	Hold	12,000	–	–	0.12%	194
2025 Q2	$1.45M	Hold	12,000	–	–	0.12%	198
2025 Q1	$1.34M	Hold	12,000	–	–	0.12%	200
2024 Q4	$1.17M	Buy	+12,000	New	+$1.28M	0.12%	192

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Generali Investments CEE's NVS Position: Q2 2026 in Review

Generali Investments CEE held its Novartis (NVS) position steady in Q2 2026 at 12,000 shares worth $1.88M. The position accounts for 0.09% of the portfolio, ranked #220.

Generali Investments CEE first reported a position in NVS in Q4 2024 and has held it in 7 quarters since. 1,625 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Generali Investments CEE held 12,000 shares of Novartis worth $1.88M as of Q2 2026.
Generali Investments CEE left its Novartis share count unchanged in Q2 2026.
Novartis made up 0.09% of Generali Investments CEE's portfolio in Q2 2026, its #220 holding.
Generali Investments CEE first reported a position in Novartis in Q4 2024 and has held it in 7 quarters since.
1,625 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Generali Investments CEE's 13F filing for Q2 2026, filed 13 Jul 2026.